X

This site uses third parties to own and optimize your navigation and perform analytical work cookies. If you continue browsing, consider that you accept its use.
You can learn more at our Cookie Policy.

Innoprot

AD Model - APP Processing Assay

Data Sheet



 Alzheimer’s Disease (AD) is characterized by brain depositions of the beta amyloid (bA). The bA is the amyloid precursor protein (APP) digestion product, which is released from the cell after b-secretase and  g-secretase proteolysis. A novel fluorescence-based assay for screening of inhibitors of the APP Processing pathway has been developed and fully validated with reference compounds.


Assay Details


MDCK stably expressing human APP-tGFP cells are treated with 6 log dilution series (n=4) of potential inhibitors during 72 hours to evaluate their effects against Aβ peptide synthesis. When APP processing is stopped by any compound, retained fluorescent APP spots are formed. After that, the nucleus was stained with DAPI and cells with retained APP spots were detected and quantified by fluorescence using image analysis.

Applications

 

Request for Quotation



© Innoprot 2008 - Cell Based Assays for Drug Discovery Screening - Cookie Policy